welcome conference Thank full everyone I'm much, you And for and call earnings operator. fourth Officer and the LaViscount, year Medical's on COO. XXXX Joyce our call. Financial Helius joined quarter by so today Chief
Canada Let during me start you a fourth a by the now are will to of our with to we progress intend the FDA. quick agenda where have recap provide we quarter that the include two operational followed update we topics the and U.S. going commercialize of progress with on in our update an primarily today. in on discussion an the discussion progress results I'm countries the recent recent with financial begun cover brief PoNS our our focused on our U.S. treatment This where to Canada and
our we press to pleased with our remarks, for a XXXX revenue-generating full the Helius's the which share to we Joyce Beginning Following the to call recap this quarter and in opening some results guidance I'll report our release is of XX, earnings detail afternoon. review ended will come the I'll call XXXX, where financial Helius these focused in December fourth additional on discuss years our to turn QX year XXXX then are and areas who history. thoughts and first over for quarter in our the results, greater key introduced questions. in very financial brief before
for company recognized agreement of and Connex fee called HealthTech XXXX, have is with the quarter for fee the clinics Canada. PoNS of Canada. replicable entity license Canadian entitled alliance clinic to Heuro facilitate that our and expansion this this the is strategic patients the to rights we Canada, Helius Canada. for which the model we related neuroplasticity the of relationship receive its We commercialization creation granted Under in to operating Heuro agreement, $XXX,XXX we the responsible future license During treatment to development believe HealthTech of treat fourth important revenue from in Connex will of
costs primarily decreased million, to fourth XX.X in product reduced operating development our approximately the XX, December fourth cash XXXX. of quarter XXXX, of by $XXX,XXX million XX, X.X compared the was which X.X million was quarter at as December Our XXXX to driven expenses XXXX, to of balance compared and
strategic of shareholders would the and and which Oppenheimer balance our approximately of pricing in important to underwritten I offering. net During growth our like support proceeds strengthen new with who we public successful our in sheet we led to XX.X offering, an the fourth capital quarter, participated million. raised thank and initiatives this existing by BTIG raised
by the therapy and progress estimate We possible Canada addressable will this Canadians agency's With meets the injury and available important progress represent balanced Canadian where PoNS than an operational fourth are living population patients during license the recent in we and months, Moving very we've accessible device adjunct quarter on from mild-to-moderate Helius patient our to an Canada deficit as widely therapy treatment underserved Medical patient for effectiveness an Canada, XXX,XXX mind, for as XX,XXX and our and to chronic to in additional received that our deficit an pleased first first believe be we due recent commercializing focused update are this subsequent is safety treatment physical that We requirements chronic months. with October, we is In population. us brain in only mild-to-moderate importantly or PoNS that addresses mmTBI as PoNS Canada on Technologies. patients adequately in device we made medical there the treatment our each making balance certifies PoNS which year. diagnosed and Health a that and more are with we TBI. and in to country market patients traumatic treatment allows quality to the are PoNS believe and
this agreement Canada. avoiding months, During the PoNS Heuro fund an as same allow our HealthTech in as extensive alliance believe treatment important the need to an announced that is strategic cost-effectively development by of we our Canada us commercial alliance efficiently We will infrastructure. strategic Connex possible to and the and agreement with commercialize
treatment. in provider. In support quality requisite also including intensely with training our commercialization recent During as Canada our in to continue expanding focused and the treatment We on our by their selecting PoNS delivery PoNS of as infrastructure clinics and the fourth of make system quarter, partnering our system, a to we our our third-party management Canada. have stride our infrastructure in system important assessments our commercialize to to months, marketing establishing our our been first surveillance well distribution two these post infrastructure clinics distribution neuroplasticity provide of teams completed engaged logistics and PoNS treatment
we company's of the treatment across possible the with the my for these they were PoNS commercial-stage first I working On country. representative beginning opportunity efforts, satisfying earlier for to treatment neuroplasticity our transition their because life. patients result organization of clinics. clinics had important the our and a while me neuroplasticity treated by in key treating and patients earlier geographic one our the in As to Canadian most in note, March, in most This two as was They the forward new professionally engage many two one visit we after of these in company being clinics a in certified history, as clinics at look one areas of to as thank patients requested milestones the into my this is exciting marking an incredibly events point inflection these these this celebrated the bringing our to the early wanted This very of collectively lives of related a personally treatment. of treatment. week experiencing request of who benefit as presence easily to a company
to to from be future the in for other regulators. launch relationships established approval expected third-party PoNS We variety FDA the our and coverage, successful experience will paid. from markets in to we receive commercial treatment our to expect us in for marketing help our the gained collaborate other and also We've U.S. their Canada pay we Canada provide are prepare patients largely patients cash once advance In of establishing of broad-based reimbursement to with treatment. a companies initial with options financing commercializing
the and expectations future intend of in I'll anonymized reimbursement remarks. PoNS which data on patients markets where used device the economic prepared be pursuit will health treated Canada in also for is neuroplasticity Canada of to the We more our specific share gather clear clinics, commercialized. and our my coverage later in to support and
XXX(k) submitted progress Turning XXXX, Administration. on investigation update our and Drug and of clearance the XX, device in novo of regulatory to classification the on U.S., request our U.S. PoNS we with an for de our Food August
multiyear that data, request classification we this our for As XXX regulatory regulatory January to establishing support culmination for of milestone controlled PoNS clinical AI clearance. and novel our from included package an the preparing enrollment information FDA our a which important extensive strategic of two novo safety received related participants a to a with the demonstrating submission XXX(k) request trials with and On device technology. of double-blind we effort, important this combined a de including randomized and XXXX, additional for reminder, efficacy announced clinical or clearance submission letter XX, of
the of the request a to a a the FDA part are the substantive review additional additional agency completed to necessary XXX to or is companies XXX(k) days process complete As After to option has of continue provided for that submit review. to de novo receiving review information, information request With believes resume the team review. pleased like request information timely such announce by AI, additional to mind, in in preparing FDA FDA for item regulatory I'm our in congratulate each to we that this a their response response to an I'd letter to request. FDA submitted our fashion. to very phase allowing
of submission the In regulatory focused the in programs review FDA's experience our our we are also addition on PoNS treatment. for to facilitating U.S., establishing clinical
centers clinical As advance as study chronic of by the and in at established PoNS independent provide with enable These part high institutional treatment include an neurorehabilitation or neurorehabilitation to by open academic of institutions, a hospital U.S., reminder, boards. CEP programs early system, label our clinical therapist deficit train and physical which Helius balance Helius centers clearance and review FDA in in approved adopter, leading, research volume to programs individuals sponsored with are experience centers. these partnership
TBI; clinical opinion these were Our model; as the of accomplish support neurorehabilitation believe we proposed field the our strategy designed help reimbursement One, following of used to obtain evidence insurers and three, leaders to accumulate providing with our gain treatment. to broad leading world our further in in and validate experience patients setting, with part real key experience which be centers treatment clinical goals. discussions of important the programs our number our with will PoNS three relationships clinical early in to to us adapter in two, commercial for PoNS number build
in PoNS the patients economic now clinics. Given to commercializing the we intend treatment neuroplasticity we the Canadian data that treated Canada, are from in health gather
the the focus We the and data have intervening coverage. of we to and We in that patient important Ohio; and pursuit University for important believe this to in September Feinstein Wexner Columbus, with and Institute partnership of at for XXXX. Research Ohio and Health's Center first the generate payers Texas. we our clinical We following Medical Medical York; for with Rehabilitation Oregon; durability Feinstein additional participating and State and support CEPs Foundation Dallas, will The site Institute in to our of Hanover, for activities since at discuss progress Medical durability enrolling validation Center thus months and Northwell Ohio XXXX to broad-based established Consistent in for in clinical the patients our in five greater new total other of Research the the announced University detail X Portland, including The CEP Jersey; our at and New Medical make Institute sites for Wexner outcomes treatment our added moment. Institute order a the end institutions. at a our post-PoNS expectations further New on in treatment. the amended Research Health’s obtaining I'll on reimbursement resonate XXXX began XX Kessler provide Northwell protocols the have University both in our in Oregon State in expectations, PoNS months, of Science with evidence with in recruiting Manhasset, CEP in Baylor partnerships on continue support Kessler Health
Before Diane aware of results, are short HR, serve I report. to PoNS COO, on Counsel, in professional organization innovative through CFO with any QX operate professionals will Joyce over ourselves misleading My this assorted to the continue our and mmTBI it we as facts and Officer, General disparaging Medical devote treatment and to ethical in of comments staff report Company's false changing guidelines January Sackier; XX to shareholders, walk staff, and Joyce financial. statements and the for began to Ito Commercial Head with under by numerous and you executive Chief I patients treatment. PoNS released acknowledge of myself the Officer, Jonathan our undue this going of LaViscount; full healthcare as professional lives a wanted the fourth and of employees affected Carman; year. Joyce Laux; Ellyn simply year quarter attention Joyce? not the now exemplary will the Chief executive we our along those I'm and my XXXX impose that Jennifer turn we of through
